IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing

References

• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
   Google Scholar
• Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121:5154-7; PMID:23678006; http://dx.doi.org/10.1182/blood-2013-02-485623
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20:119-22; PMID:24667956; http://dx.doi.org/10.1097/PPO.0000000000000035
   PubMed Web of Science ®Google Scholar
• Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunolgy 2001; 2:711-7; PMID:11477407; http://dx.doi.org/10.1038/90650
   PubMedGoogle Scholar
• Richer MJ, Nolz JC, Harty JT. Pathogen-specific inflammatory milieux tune the antigen sensitivity of CD8(+) T cells by enhancing T cell receptor signaling. Immunity 2013; 38:140-52; PMID:23260194; http://dx.doi.org/10.1016/j.immuni.2012.09.017
   PubMed Web of Science ®Google Scholar
• Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF. Programming for CD8 T cell memory development requires IL12 or type I IFN. J Immunol 2009; 182:2786-94; PMID:19234173; http://dx.doi.org/10.4049/jimmunol.0803484
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999; 162:3256-62; PMID:10092777
   PubMed Web of Science ®Google Scholar
• Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4:573-81; PMID:8673704; http://dx.doi.org/10.1016/S1074-7613(00)70060-4
   PubMed Web of Science ®Google Scholar
• de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 2014; 92:237-44; PMID:24343663; http://dx.doi.org/10.1038/icb.2013.95
   PubMed Web of Science ®Google Scholar
• Verhoeven DHJ, de Hooge ASK, Mooiman ECK, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol MJ et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-25; PMID:18657862; http://dx.doi.org/10.1016/j.molimm.2008.06.016
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119:1251-63; PMID:19349689; http://dx.doi.org/10.1172/JCI36022
   PubMed Web of Science ®Google Scholar
• Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunol Immunother 2015; 64:409-18; PMID:25549845; http://dx.doi.org/10.1007/s00262-014-1648-2
   PubMed Web of Science ®Google Scholar
• Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K, Nakayama E, Nakauchi H, Shibuya A. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999; 11:615-23; PMID:10591186; http://dx.doi.org/10.1016/S1074-7613(00)80136-3
   PubMed Web of Science ®Google Scholar
• Wölfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, Schlegel PG. Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother 2011; 60:173-86; PMID:20972785; http://dx.doi.org/10.1007/s00262-010-0928-8
   PubMed Web of Science ®Google Scholar
• Wölfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc 2014; 9:950-66; PMID:24675735; http://dx.doi.org/10.1038/nprot.2014.064
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010; 22:333-40; PMID:20363604; http://dx.doi.org/10.1016/j.coi.2010.02.013
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174:4465-9; PMID:15814665; http://dx.doi.org/10.4049/jimmunol.174.8.4465
   PubMed Web of Science ®Google Scholar
• Freeman BE, Hammarlund E, Raué H-P, Slifka MK. Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A 2012; 109:9971-6; PMID:22665806; http://dx.doi.org/10.1073/pnas.1203543109
   PubMed Web of Science ®Google Scholar
• Beadling C, Slifka MK. Differential regulation of virus-specific T-cell effector functions following activation by peptide or innate cytokines. Blood 2005; 105:1179-86; PMID:15471952; http://dx.doi.org/10.1182/blood-2004-07-2833
   PubMed Web of Science ®Google Scholar
• van Wely CA, Beverley PC, Brett SJ, Britten CJ, Tite JP. Expression of L-selectin on Th1 cells is regulated by IL12. J Immunol 1999; 163:1214-21; PMID:10415016
   PubMed Web of Science ®Google Scholar
• Romero P, Speiser DE, Rufer N. Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans. Eur J Immunol 2014; 44:2567-70; PMID:25154881; http://dx.doi.org/10.1002/eji.201445004
   PubMed Web of Science ®Google Scholar
• Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005; 11:4545-52; PMID:15958640; http://dx.doi.org/10.1158/1078-0432.CCR-04-2235
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Dotti G, Hasan ST, Angelis Bd, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM et al. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011; 117:3353-62; PMID:21278353; http://dx.doi.org/10.1182/blood-2010-08-300376
   PubMed Web of Science ®Google Scholar
• Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunol Immunother 2012; 61:385-96; PMID:21928126; http://dx.doi.org/10.1007/s00262-011-1111-6
   PubMed Web of Science ®Google Scholar
• Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330-9; PMID:18395492; http://dx.doi.org/10.1016/j.clim.2008.02.006
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011; 118:3301-10; PMID:21821703; http://dx.doi.org/10.1182/blood-2011-02-336321
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198:557-67; PMID:12913096; http://dx.doi.org/10.1084/jem.20030788
   PubMed Web of Science ®Google Scholar
• Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015; 15:243-54; PMID:25743219; http://dx.doi.org/10.1038/nri3799
   PubMed Web of Science ®Google Scholar
• Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL, Shibuya A. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 2004; 16:533-8; PMID:15039383; http://dx.doi.org/10.1093/intimm/dxh059
   PubMed Web of Science ®Google Scholar
• Roskoski R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331:1-14; PMID:15845350; http://dx.doi.org/10.1016/j.bbrc.2005.03.012
   PubMed Web of Science ®Google Scholar
• Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010; 22:339-48; PMID:19861160; http://dx.doi.org/10.1016/j.cellsig.2009.10.003
   PubMed Web of Science ®Google Scholar
• Johnson KG, Bromley SK, Dustin ML, Thomas ML. A supramolecular basis for CD45 tyrosine phosphatase regulation in sustained T cell activation. Proc Natl Acad Sci U S A 2000; 97:10138-43; PMID:10963676; http://dx.doi.org/10.1073/pnas.97.18.10138
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 2014; 257:145-64; PMID:24329795; http://dx.doi.org/10.1111/imr.12141
   PubMed Web of Science ®Google Scholar
• Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PloS One 2011; 6:e22560; PMID:21829468; http://dx.doi.org/10.1371/journal.pone.0022560
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx.doi.org/10.1016/S1359-6101(01)00032-6
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13:4677-85; PMID:17699845; http://dx.doi.org/10.1158/1078-0432.CCR-07-0776
   PubMed Web of Science ®Google Scholar
• Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013; 2:e25961; PMID:24083084; http://dx.doi.org/10.4161/onci.25961
   PubMed Web of Science ®Google Scholar
• Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014; 63:419-35; PMID:24514955; http://dx.doi.org/10.1007/s00262-014-1523-1
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-targeted T cells modified to secrete IL12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133-41; PMID:22354001; http://dx.doi.org/10.1182/blood-2011-12-400044
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 2015; 4:e994446; PMID:25949921; http://dx.doi.org/10.4161/2162402X.2014.994446
   PubMed Web of Science ®Google Scholar
• Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams KM, Johnson CB, Li M et al. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother 2015; 64(5):539-49; PMID:25676709; http://dx.doi.org/10.1007/s00262-015-1655-y
   PubMed Web of Science ®Google Scholar
• Weinstein-Marom H, Pato A, Levin N, Susid K, Itzhaki O, Besser MJ, Peretz T, Margalit A, Lotem M, Gross G. Membrane-attached Cytokines Expressed by mRNA Electroporation Act as Potent T-Cell Adjuvants. J Immunother 2016; 39:60-70; PMID:26849075; http://dx.doi.org/10.1097/CJI.0000000000000109
   PubMed Web of Science ®Google Scholar
• Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother 2013; 62:727-36; PMID:23207483; http://dx.doi.org/10.1007/s00262-012-1378-2
   PubMed Web of Science ®Google Scholar
• Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T et al. Cancer-targeted IL12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology 2015; 4:e1014760; PMID:26140238; http://dx.doi.org/10.1080/2162402X.2015.1014760
   PubMedGoogle Scholar
• Salgado FJ, Lojo J, Alonso-Lebrero JL, Lluis C, Franco R, Cordero OJ, Nogueira M. A role for interleukin-12 in the regulation of T cell plasma membrane compartmentation. J Biol Chem 2003; 278:24849-57; PMID:12676959; http://dx.doi.org/10.1074/jbc.M212978200
   PubMed Web of Science ®Google Scholar
• Geldern Mv, Simm B, Braun M, Weiss EH, Schendel DJ, Falk CS. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I. Eur J Immunol 2006; 36:2347-58; PMID:16909431; http://dx.doi.org/10.1002/eji.200535387
   PubMed Web of Science ®Google Scholar
• Helms MW, Prescher JA, Cao Y-A, Schaffert S, Contag CH. IL12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer immunol Immunother 2010; 59:1325-34; PMID:20532883; http://dx.doi.org/10.1007/s00262-010-0860-y
   PubMed Web of Science ®Google Scholar
• Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A. The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol 2014; 4:508; PMID:24432022; http://dx.doi.org/10.3389/fimmu.2013.00508
   PubMed Web of Science ®Google Scholar
• Ely KH, Cauley LS, Roberts AD, Brennan JW, Cookenham T, Woodland DL. Nonspecific recruitment of memory CD8+ T cells to the lung airways during respiratory virus infections. J Immunol 2003; 170:1423-9; PMID:12538703; http://dx.doi.org/10.4049/jimmunol.170.3.1423
   PubMed Web of Science ®Google Scholar
• Ho WY, Nguyen HN, Wolfl M, Kuball J, Greenberg PD. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J Immunol Methods 2006; 310:40-52; PMID:16469329; http://dx.doi.org/10.1016/j.jim.2005.11.023
   PubMed Web of Science ®Google Scholar